| Stage | MORN | % of rev | BX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $672M | 100.00% | $5.0B | 100.00% | BX ×7.50 |
| Gross profit | $431M | 64.19% | $5.0B | 100.00% | BX +35.8pp |
| Operating income | $167M | 24.91% | $2.7B | 52.90% | BX +28.0pp |
| Pre-tax income | $152M | 22.68% | $2.8B | 55.68% | BX +33.0pp |
| Net income | $116M | 17.18% | $2.4B | 46.71% | BX +29.5pp |
| Stage | MORN | BX | Gap · A − B |
|---|---|---|---|
| Revenue | $672M100.00% | $5.0B100.00% | BX ×7.50 |
| Gross profit | 64.19%$431M | 100.00%$5.0B | BX +35.8pp |
| Operating income | 24.91%$167M | 52.90%$2.7B | BX +28.0pp |
| Pre-tax income | 22.68%$152M | 55.68%$2.8B | BX +33.0pp |
| Net income |
| 17.18%$116M |
| 46.71%$2.4B |
| BX +29.5pp |
No shared counterparties.